GSK Acquires Chinese-developed Trispecific Antibody CMG1A46 for $300M Upfront to Target Autoimmune Diseases
GSK
Pharmaceutical R&D Manufacturer
On October 29, GSK announced: an agreement reached with Chinese company Chimagen Biosciences,Acquire Chimagen Biosciences' research variety CMG1A46 with a $300 million upfront payment.In addition, subsequent development and commercial milestone payments could reach up to 550 million US dollars.
CMG1A46 is a tri-specific antibody targeting CD3/CD19/CD20, used for treating various drug-resistant and relapsed B-cell hematological tumors.Is the world's first to enterClinicalThe anti-CD3/CD19/CD20 tri-specific antibody product，Currently in Phase I clinical trials for leukemia and lymphoma in the United States and China.
According to the announcement, GSK plans to focus on CMG1A46 inPotential in treating systemic lupus erythematosus and lupus nephritis，And it may potentially expand to other autoimmune diseases. GSK plans to conduct a Phase I clinical trial for systemic lupus erythematosus in the first quarter of 2025.
Chimagen Biosciences was founded in 2016 in Chengdu High-Tech Zone and incubated by Chengdu High-Tech Venture Capital Co., Ltd. The company focuses on developing multi-specific T-cell engagers and NK-cell engagers. CMG1A46, the subject of this transaction, is its lead pipeline.In December 2021, Bright Biology introduced the Greater China rights to this drug.
By reporter Li Ao
Editor | Jiang Yun, Jia Ting
Operation｜Twenty-thirteen
